iShares Core High Dividend ETF vs 22nd Century Group Inc — how do they compare? iShares Core High Dividend ETF trades at $28.75 (market cap $14.68B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: iShares Core High Dividend ETF is far larger — about 23613.8× 22nd Century Group Inc's market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and 22nd Century Group Inc for 32 Days on average.
| HDV | XXII | |
|---|---|---|
Market Cap | $14.68B | $621.67K |
Volume | 2,925,562 | 45,625 |
52-Week High | $29.93 | $483.00 |
52-Week Low | $23.64 | $0.80 |
Typical Hold Time | 117 Days | 32 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.71, up 1.52% with a bullish technical signal. Recent sector rebalancing reduced healthcare exposure by nearly half while increasing energy, staples, and utilities, creating concentration risk with 62% in three sectors. The ETF yields approximately 3% but faces questions about whether this compensates for reduced diversification. Technical indicators show strong momentum with RSI at 77.74 suggesting potential overbought conditions.
The outlook remains cautiously optimistic given HDV's 2026 outperformance against the S&P 500, though the concentrated sector allocation and moderate yield present both opportunity and risk. Investors should weigh the fund's recent structural changes against its dividend income generation capabilities in a rising rate environment.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →